Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975790 · ClinicalTrials.gov registry record
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX
A clinical trial of Rheumatoid Arthritis, sponsored by Pfizer.
- Completed
- Registry status
- 479
- Enrollment target
- 1
- Study location
NCT03975790 is a study of Rheumatoid Arthritis that has completed, run by Pfizer. The registered enrollment target is 479 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03975790, a study of Rheumatoid Arthritis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 479 participants
- Enrollment target
- 1
- Study location
Study Summary
To address the objectives, a retrospective cohort design will be employed to evaluate patient characteristics, treatment patterns, medication effectiveness, and health care cost and utilization in RA patients newly initiating tofacitinib in combination with oral methotrexate (MTX)
Conditions Studied
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2018-10-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03975790
The ClinicalTrials.gov registry entry for NCT03975790 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (90% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT03975790 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03975790 about?
NCT03975790 is a clinical study titled "Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX". To address the objectives, a retrospective cohort design will be employed to evaluate patient characteristics, treatment patterns, medication effectiveness, and health care cost and utilization in RA patients newly initiating tofacitinib in combination with oral methotrexate (MTX)
What is the current status of trial NCT03975790?
This trial is currently completed. The enrollment target is 479 participants. The study started on 2018-05-29. Estimated completion is 2018-10-02.
What conditions does trial NCT03975790 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
Who is sponsoring clinical trial NCT03975790?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03975790 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.